Exparel 266 MG/20 ML vial 20ML
Ended Awarded Last action
- Contract number
- SPE2DR26FCZF3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $30,808
Award facts
- Contract value 100% obligated
- $30,807.84 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) issued a delivery order valued at $30,807.84 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL (liposomal bupivacaine) 266 mg/20 mL vials. The award, dated January 12, 2026, with an ultimate completion date of February 3, 2026, was issued on a firm fixed-price basis without set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. This delivery order falls under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was established on November 13, 2025, with a $499.9 billion ceiling value through December 31, 2036.
DMS Pharmaceutical Group serves as a critical regional pharmaceutical supplier within the DLA's broader $30.3 billion PPV-G GEN V acquisition strategy, supporting recurring medical supply needs for Department of Defense healthcare facilities worldwide. The company's established performance across a diverse portfolio of pharmaceutical products—including specialty surgical products, biologics, vaccines, and routine medications—demonstrates its capability to fulfill specialized requirements within the federal military medical system. No subcontractors are identified in this award documentation, with DMS Pharmaceutical Group fulfilling the supply obligation directly to support DoD healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FCZF3?
SPE2DR26FCZF3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 12, 2026.
How much is contract SPE2DR26FCZF3 worth?
The government has obligated $30,808 on SPE2DR26FCZF3.
Is contract SPE2DR26FCZF3 an order under another contract?
Yes. SPE2DR26FCZF3 is a delivery order under SPE2DR25D9127, an indefinite delivery contract.
Was contract SPE2DR26FCZF3 competed?
The extent of competition for SPE2DR26FCZF3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award